Surrozen, Inc. (SRZN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SRZN
- Company Surrozen, Inc.
- Price $32.18
- Changes Percentage 0.63
- Change 0.2
- Day Low $30.98
- Day High $33.22
- Year High $35.86
- Year Low $11.39
- Market Cap $251,839,472
- Price Avg 50 EMA (D) $21.46
- Price Avg 200 EMA (D) $24.25
- Exchange NASDAQ
- Volume 11,490,450
- Average Volume 219,296
- Open $32.24
- Previous Close $31.98
- EPS -39.55
- PE -0.85
- Earnings Announcement 2026-11-06 05:00:00
- Shares Outstanding $7,477,419
Company brief: SURROZEN, INC. (SRZN )
- Healthcare
- Biotechnology
- Mr. Craig C. Parker M.B.A.
- https://www.surrozen.com
- US
- N/A
- 01-11-2021
- US86889P2083
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.